Related Experiment Video

Updated: Jul 13, 2026

Yeast Luminometric and Xenopus Oocyte Electrophysiological Examinations of the Molecular Mechanosensitivity of TRPV4
12:09

Yeast Luminometric and Xenopus Oocyte Electrophysiological Examinations of the Molecular Mechanosensitivity of TRPV4

Published on: December 31, 2013

TRPV4: A Promising Therapeutic Target Ion Channel─Discovery of Ultrapotent Selective Antagonists

Magnus Nilsson1, Sara J Bonvini2, Emelyne Diers1

  • 1Medicinal Chemistry, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden.

Journal of Medicinal Chemistry
|July 11, 2026
PubMed

Insights

A novel small-molecule TRPV4 antagonist, compound 39, shows promise for treating conditions linked to the TRPV4 channel. It offers improved drug-like properties and demonstrated efficacy in a preclinical cough model.

Area of Science:

  • Molecular Biology
  • Pharmacology
  • Drug Discovery

Background:

  • Transient Receptor Potential Vanilloid 4 (TRPV4) is a calcium-permeable channel crucial for cellular signaling in epithelia.
  • TRPV4 antagonism is a therapeutic target, but previous attempts faced pharmacokinetic challenges, limiting clinical efficacy.

Purpose of the Study:

  • To discover and optimize novel small-molecule TRPV4 antagonists.
  • To evaluate the pharmacokinetic and safety profile of lead compound 39.
  • To assess the in vivo efficacy of compound 39 in a relevant disease model.

Main Methods:

  • High-throughput screening was employed to identify initial TRPV4 antagonist hits.
  • Lead optimization focused on enhancing potency, selectivity, and drug-like properties.
  • Preclinical in vivo studies, including a cough model, were used to assess efficacy and safety.

Main Results:

  • A novel series of TRPV4 antagonists was developed, with compound 39 emerging as the lead candidate.
  • Compound 39 exhibited favorable absorption and elimination, suggesting a potential for once-daily oral dosing.
  • Early safety studies indicated robust margins to off-target effects, and compound 39 demonstrated functional efficacy in a preclinical cough model.

Conclusions:

  • Compound 39 represents a differentiated preclinical TRPV4 antagonist with promising drug-like pharmacokinetics.
  • The favorable nonclinical safety profile and demonstrated efficacy support further development of compound 39 for therapeutic applications.

More Related Videos

High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels10:07

High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels

Published on: January 27, 2013

Related Concept Videos

Non-gated Ion Channels01:24

Non-gated Ion Channels

Ion channels are specialized proteins on the plasma membrane that allow charged ions to pass down their electrochemical gradient. Their main function is to maintain the membrane potential which is critical for cell viability. These channels are either gated or non-gated and can transport more than a thousand ions within milliseconds for the cellular event to occur.
Compared to the gated ion channels, the non-gated channels, also known as leakage or passive channels, have no gating mechanism.
Non-gated Ion Channels01:24

Non-gated Ion Channels

Ion channels are specialized proteins on the plasma membrane that allow charged ions to pass down their electrochemical gradient. Their main function is to maintain the membrane potential which is critical for cell viability. These channels are either gated or non-gated and can transport more than a thousand ions within milliseconds for the cellular event to occur.
Compared to the gated ion channels, the non-gated channels, also known as leakage or passive channels, have no gating mechanism.
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Ion Channels01:19

Ion Channels

The movement of ions like sodium, potassium, and calcium into and out of the cell is essential to maintain the electrochemical gradient in living cells. The ion channels—a class of membrane transport proteins—help maintain this ionic gradient for the smooth functioning of physiological activities such as maintaining cell size and volume, conducting nerve impulses, and gas and nutrient exchange.
Ion channels are specialized integral membrane proteins on the plasma membrane that allow specific...
Mechanically-gated Ion Channels01:12

Mechanically-gated Ion Channels

Mechanically-gated ion channels are proteins found in eukaryotic and prokaryotic cell membranes that open in response to mechanical stress. Tension, compression, swelling, and shear stress can alter the conformation of the protein, opening a transmembrane channel that allows the passage of ions for signal transmission. In eukaryotes, mechanically-gated channels are distributed in several regions like the neurons, lungs, skin, bladder, and heart, where they play critical roles in numerous...
Mechanically-gated Ion Channels01:12

Mechanically-gated Ion Channels

Mechanically-gated ion channels are proteins found in eukaryotic and prokaryotic cell membranes that open in response to mechanical stress. Tension, compression, swelling, and shear stress can alter the conformation of the protein, opening a transmembrane channel that allows the passage of ions for signal transmission. In eukaryotes, mechanically-gated channels are distributed in several regions like the neurons, lungs, skin, bladder, and heart, where they play critical roles in numerous...